EMEA-001971-PIP02-16-M04
Key facts
| Invented name |
Vitrakvi
|
| Active substance |
Larotrectinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0487/2021
|
| PIP number |
EMEA-001971-PIP02-16-M04
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)
|
| Route(s) of administration |
|
| Contact for public enquiries |
Bayer AG
Tel. +49 3046815333 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|